Pharmaceutical Executive Daily: New Research on Ozempic
Pharmaceutical Executive Daily covers the latest news in the pharmaceutical and life sciences industry.
The FDA has approved Bayer’s Lynkuet for menopausal hot flashes. Lynkuet, also known as elinzanetant, is the first dual neurokinin 1 and 3 receptor antagonist for the treatment of moderate to severe vasomotor symptoms associated with menopause.
Research suggests Ozempic may reduce biological age. Additionally, Novartis has a $12 billion merger agreement to acquire Avidity Biosciences.
Lynkuet’s approval is based on Phase III OASIS trial data showing significant reductions in hot flash frequency and severity. As a non-hormonal option, Lynkuet provides an alternative for patients seeking relief from menopausal symptoms without estrogen exposure.
No direct quote available in the given text.
Author’s summary: Pharmaceutical Executive Daily covers industry news.
More News
- From proof of concept to powerhouse: Why federal agencies need AI factories
- Acclime Acquires Crowe Singapore to Create Regional Professional Services Powerhouse | AAP
- Can MAGA Conservatives and Muslim Americans Unite?
- The Renters’ Rights Act becomes Law: Securing a fairer future for 11 million renters
- MMJ BioPharma Cultivation: EXPOSÉ: DEA's Marijuana Licensing Scheme Exposed - MMJ BioPharma's Case Reveals DEA Contradiction Blocking FDA Approved Cannabis Medicine
- The FDA Withholds Names of Drugs Made in Contaminated Factories
- Emma Thompson Explodes in Rage Over the 'Intense Irritation' of AI: 'Will You F--k Off?!' | Video
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- Tackling youth vaping: Current regulations fall short and new tech offers effective solutions